Objective To study the diagnostic value of miR-571 for liver fibrosis by detecting miR-571 expression in the peripheral blood of patients with liver fibrosis. Methods From December 2022 to September 2023， 40 patients with liver fibrosis， 40 patients with chronic hepatitis， and 40 healthy controls were chosen as research subjects. The expression level of miR-571 in peripheral blood was detected using a real-time quantitative polymerase chain reaction， and the relative expression of miR-571 in each group was evaluated. The Spearman correlation method was utilized to examine the relationship between miR-571 and clinical detection indices. To assess the capacity of miR-571 and the multivariate diagnostic model to identify liver fibrosis， binary logistic regression was used to create a multivariate diagnostic model， and ROC curves were generated. Results The expression of miR-571 was significantly higher in the liver fibrosis group than in the healthy control and hepatitis groups， and the difference was statistically significant （P < 0.001）. The expression level of miR-571 was positively connected with ALT， APRI score， and FIB-4 index （r = 0.23， 0.30， 0.22， P < 0.05） and negatively correlated with PLT （r = -0.19， P < 0.05） according to Spearman correlation analysis. Logistic regression research revealed that miR-571 and the FIB-4 index were independent risk factors for liver fibrosis. The AUC for miR-571 to diagnose fibrosis was 0.91 （95% CI： 0.85 ~ 0.96）， while the AUC for miR-571 paired with the FIB-4 index was 0.94 （95% CI： 0.90 ~ 0.98）. Conclusion MiR-571 expression was shown to be considerably higher in the peripheral blood of hepatic fibrosis patients， and the combined FIB-4 index offers some clinical diagnostic value for hepatic fibrosis.